Real-World Data on Metastatic Lung Cancer: Cost Analyses in Brazil From a Private Insurance Company's Perspective
JCO Global Oncology · 2025
DOI: 10.1200/go-24-00253 ↗Kurz gefasst
Fachartikel in der Zeitschrift JCO Global Oncology, 2025. Verfasst von Rodrigo Afonso da Silva Sardenberg und 6 weiteren Autor:innen. Beteiligte Einrichtung: Instituto Americas, São Paulo, Brazil. Hauptthemen laut MEDLINE: Lung Neoplasms, Carcinoma, Non-Small-Cell Lung. Die Arbeit nennt 30 Literaturangaben.
Abstract (Originalsprache)
PURPOSE Non–small cell lung cancer (NSCLC) is often diagnosed at late stages, leading to escalated treatment expenses. This study aimed to elucidate the costs of lung cancer treatment in a private health care setting in Brazil. MATERIALS AND METHODS We conducted a retrospective cohort study, regarding costs, survival, and quality of care of stage IV NSCLC in a private health company in Brazil. RESULTS A total of 819 individuals were included, with median age 64.9 years. With a 1-year follow-up, patients had a median of four hospital admissions, with a median length of stay in of 6.2 days. Survival rates were higher for patients treated with targeted therapy (hazard ratio [HR], 0.38 [95% CI, 0.25 to 0.56]), immunotherapy (HR, 0.52 [95% CI, 0.40 to 0.68]), or both treatments sequentially (0.41 [95% CI, 0.25 to 0.68]). Patients submitted to sequentially targeted therapy and immunotherapy had the higher total costs (mean, $172,828 USD) compared with patients treated with immunotherapy (mean, $138,125 USD), targeted therapy (mean, $117,068 USD), and only chemotherapy (mean, $47,625 USD). As expected, longer survival was translated into more third-line therapy ( P < .001), and higher mean costs with cancer-related hospital admissions ($24,554 USD chemo, $31,835 USD immuno, $28,228 USD targeted, and $35,494 USD for both therapies). However, costs did not increase in proportion to the survival benefit. Despite longer survival, patients undergoing targeted therapy or immunotherapy had median number of hospital admissions and length of stay similar to those who underwent chemotherapy alone. CONCLUSION Higher survival rates and costs were found for patients exposed to modern treatments for advanced NSCLC. Cost-effectiveness thresholds definitions are warranted for managing costs, particularly in developing countries.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Instituto Americas, São Paulo, Brazil.
- Centro de Pesquisa Internacional do Hospital Alemão Oswaldo Cruz, São Paulo, Brazil.
- Instituto Americas, Rio de Janeiro, Brazil.
ORCID-Profile: Mariana Ribeiro Monteiro, Cinthia Leite Frizzera Borges Bognar, Rodrigo de Carvalho Moreira, Henry Sznejder
Zitieren
APA
Sardenberg, R. A. D. S., Monteiro, M. R., Bognar, C. L. F. B., Gondim Teixeira, V. B., de Carvalho Moreira, R., Sznejder, H., & Younes, R. N. (2025). Real-World Data on Metastatic Lung Cancer: Cost Analyses in Brazil From a Private Insurance Company's Perspective. JCO Global Oncology. https://doi.org/10.1200/go-24-00253
Vancouver
Sardenberg RADS, Monteiro MR, Bognar CLFB, Gondim Teixeira VB, de Carvalho Moreira R, Sznejder H, et al. Real-World Data on Metastatic Lung Cancer: Cost Analyses in Brazil From a Private Insurance Company's Perspective. JCO Global Oncology. 2025. doi:10.1200/go-24-00253
BibTeX
@article{Sardenberg2025,
author = {Sardenberg, Rodrigo Afonso da Silva and Monteiro, Mariana Ribeiro and Bognar, Cinthia Leite Frizzera Borges and Gondim Teixeira, Victor Braga and de Carvalho Moreira, Rodrigo and Sznejder, Henry and Younes, Riad Naim},
title = {Real-World Data on Metastatic Lung Cancer: Cost Analyses in Brazil From a Private Insurance Company's Perspective},
journal = {JCO Global Oncology},
year = {2025},
doi = {10.1200/go-24-00253}
}
EUVIMED